Global Benign Prostatic Hyperplasia (BPH) Treatment Devices Market Size By Type (Drugs, Devices), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Benign Prostatic Hyperplasia (BPH) Treatment Devices Market was valued at USD X billion in 2023 and is projected to surpass USD X billion by 2031, growing at a CAGR of X% during the forecast period from 2023 to 2031.

The market growth is primarily driven by the increasing prevalence of benign prostatic hyperplasia (BPH), the rising aging male population, and advancements in minimally invasive BPH treatment technologies. Additionally, the growing awareness of alternative treatment options and increased healthcare spending are fueling market expansion.

Medical device companies are investing in innovative treatment solutions such as laser therapies, transurethral resection procedures, and prostatic urethral lift systems, providing better patient outcomes and shorter recovery times. These technological advancements, along with improved healthcare infrastructure, are significantly propelling the demand for BPH treatment devices worldwide.

Market Drivers:

1. Increasing Prevalence of BPH:

With the rising global geriatric population, particularly in developed countries, BPH prevalence is increasing. The condition affects nearly 50% of men aged 50 and above, and its occurrence rises to over 80% in men aged 70 and older. This growing patient base is driving the demand for effective BPH treatment solutions.

2. Technological Advancements in Treatment Devices:

The BPH treatment devices market is witnessing rapid advancements in minimally invasive technologies, including UroLift, Rezūm Water Vapor Therapy, and Holmium Laser Enucleation of the Prostate (HoLEP). These innovations improve procedural efficiency, reduce hospitalization time, and minimize side effects, leading to higher adoption rates.

3. Rising Healthcare Expenditure and Accessibility to Advanced Treatments:

Governments and private healthcare providers are increasingly investing in urology care and minimally invasive surgical procedures, making BPH treatments more accessible and affordable. Improved healthcare insurance coverage and reimbursement policies further support market growth.

Market Restraints:

1. High Cost of Advanced BPH Treatment Devices:

Minimally invasive and robotic-assisted treatment devices are expensive, limiting their adoption in low-income regions. Additionally, the high cost of treatment procedures and lack of adequate reimbursement policies in some countries act as a barrier to market expansion.

2. Risk of Post-Surgical Complications and Device Failures:

Despite technological advancements, certain BPH treatment devices still carry risks such as urinary incontinence, infection, and erectile dysfunction. These risks may deter patient preference for surgical interventions, thereby restraining market growth.

Market Opportunities:

1. Growing Demand for Minimally Invasive and Non-Surgical Treatments:

The demand for minimally invasive and non-surgical options like UroLift, Prostatic Urethral Lift (PUL), and water vapor therapy is increasing due to their shorter recovery time and lower risks compared to traditional surgeries. This trend presents significant growth opportunities for device manufacturers.

2. Expansion into Emerging Markets:

Rapidly growing healthcare infrastructure in Asia-Pacific and Latin America is driving demand for cost-effective and innovative BPH treatments. Companies investing in market penetration strategies and localized manufacturing are likely to benefit from this expansion.

3. Development of AI and Robotic-Assisted BPH Treatment Devices:

The integration of artificial intelligence (AI) and robotics in BPH treatment devices is opening new avenues for precision surgery and enhanced patient outcomes. These advancements are expected to redefine the treatment landscape in the coming years.

Market by Device Type Insights:

Based on device type, the Minimally Invasive BPH Treatment Devices segment dominated the market in 2023. This segment includes laser therapy systems, prostatic urethral lift devices, and water vapor therapy systems, which are preferred for their less invasive nature, shorter recovery period, and high efficacy.

The Transurethral Resection of the Prostate (TURP) segment continues to hold a significant market share due to its long-standing effectiveness and widespread availability in hospitals and clinics.

Market by End-Use Insights:

1. Hospitals & Clinics:

Hospitals and specialized urology clinics accounted for the largest market share in 2023, owing to increased patient preference for hospital-based procedures and the availability of skilled healthcare professionals.

2. Ambulatory Surgical Centers (ASCs):

The ASCs segment is projected to grow significantly due to the shift toward outpatient procedures, cost-effectiveness, and reduced hospital stays.

3. Home Healthcare Settings:

With advancements in non-invasive treatment options, home-based BPH management solutions, such as portable laser therapy devices, are expected to witness increasing demand.

Market by Regional Insights:

1. North America:

North America dominated the BPH treatment devices market in 2023, with the United States leading due to:

High prevalence of BPH

Advanced healthcare infrastructure

Extensive adoption of cutting-edge treatment devices

2. Europe:

Europe holds a significant market share, driven by technological innovations in urological treatments, government funding for healthcare, and a growing elderly male population.

3. Asia-Pacific:

Asia-Pacific is expected to witness the highest CAGR during the forecast period, owing to:

Rising healthcare investments

Increasing awareness of minimally invasive BPH treatment options

Expanding medical device industry in countries like China, India, and Japan

4. Latin America and Middle East & Africa:

These regions are emerging markets for BPH treatment devices, driven by improving healthcare access and increasing medical tourism.

Competitive Scenario:

Key players in the Global BPH Treatment Devices Market include:

Boston Scientific Corporation

Teleflex Incorporated

KARL STORZ SE & Co. KG

Lumenis Ltd.

UroLift (Teleflex)

Olympus Corporation

Medtronic plc

Procept BioRobotics

Key Developments:

In 2023, Boston Scientific introduced an advanced laser therapy system designed to enhance precision and minimize side effects in BPH treatments.

Teleflex Incorporated expanded its UroLift portfolio in 2024, targeting minimally invasive treatment solutions for BPH.

Medtronic plc announced its entry into the robotic-assisted BPH treatment market, enhancing competition in the field.

Scope of Work – Global Benign Prostatic Hyperplasia (BPH) Treatment Devices Market

Report Metric Details

Market Size (2023) USD X billion

Projected Market Size (2031) USD X billion

CAGR (2023-2031) X%

Key Segments by Device Type Minimally Invasive BPH Treatment Devices, TURP, Laser Therapy Systems

Key Segments by End-Use Hospitals & Clinics, Ambulatory Surgical Centers, Home Healthcare Settings

Leading Region North America

Key Players Boston Scientific, Teleflex, KARL STORZ, Lumenis, Medtronic, Olympus

FAQs:

1. What is the current market size of the Global Benign Prostatic Hyperplasia (BPH) Treatment Devices Market?

The market was valued at USD X billion in 2023 and is expected to grow significantly.

2. What is the major growth driver of the BPH treatment devices market?

The market is driven by the increasing prevalence of BPH, technological advancements, and the shift toward minimally invasive treatments.

3. Which region dominates the BPH treatment devices market?

North America leads due to its well-established healthcare infrastructure and adoption of advanced BPH treatment devices.

4. Which segment accounted for the largest market share?

The Minimally Invasive BPH Treatment Devices segment holds the largest market share.

5. Who are the key market players?

Key players include Boston Scientific, Teleflex, KARL STORZ, Lumenis, Medtronic, and Olympus Corporation.